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Glasgow, Glasgow, Scotland, UKA B S T R A C TClinical trials evaluating medicines, medical devices, and procedures
now commonly assess the economic value of these interventions. The
growing number of prospective clinical/economic trials reﬂects both
widespread interest in economic information for new technologies
and the regulatory and reimbursement requirements of many coun-
tries that now consider evidence of economic value along with clinical
efﬁcacy. As decision makers increasingly demand evidence of eco-
nomic value for health care interventions, conducting high-quality
economic analyses alongside clinical studies is desirable because they
broaden the scope of information available on a particular interven-
tion, and can efﬁciently provide timely information with high internal
and, when designed and analyzed properly, reasonable external
validity. In 2005, ISPOR published the Good Research Practices for
Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-
CEA Task Force report. ISPOR initiated an update of the report in 2014
to include the methodological developments over the last 9 years. This
report provides updated recommendations reﬂecting advances in
several areas related to trial design, selecting data elements, databaseee front matter Copyright & 2015, International S
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.1016/j.jval.2015.02.001
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w Avenue North, M3-B232, Seattle, WA 98109.design and management, analysis, and reporting of results. Task force
members note that trials should be designed to evaluate effectiveness
(rather than efﬁcacy) when possible, should include clinical outcome
measures, and should obtain health resource use and health state
utilities directly from study subjects. Collection of economic data
should be fully integrated into the study. An incremental analysis
should be conducted with an intention-to-treat approach, comple-
mented by relevant subgroup analyses. Uncertainty should be char-
acterized. Articles should adhere to established standards for
reporting results of cost-effectiveness analyses. Economic studies
alongside trials are complementary to other evaluations (e.g., model-
ing studies) as information for decision makers who consider evi-
dence of economic value along with clinical efﬁcacy when making
resource allocation decisions.
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Data from clinical trials that evaluate medicines, medical devices,
and procedures are now commonly used to assess the value for
money of these interventions. A growing number of clinical trials
include speciﬁc data on resource use and outcome for assess-
ment of cost-effectiveness. This growth reﬂects both widespread
interest in economic information for new technologies and the
regulatory and reimbursement requirements of many countries
that now consider evidence of economic value along with clinicaleffectiveness. In the last decade, researchers have improved the
methods used for the design, conduct, and analysis of data for
economic evaluation collected alongside clinical trials. Despite
these advances, the literature reveals a great deal of variation in
methodology and reporting of cost-effectiveness analyses (CEAs).
Improving the quality of these studies will enhance their credi-
bility and usefulness to decision makers worldwide.
Early health technology assessments (HTAs) or joint regula-
tory/HTA advice is used to communicate the potential needs for
payer decisions on reimbursement and funding [1]. Payers areociety for Pharmacoeconomics and Outcomes Research (ISPOR).
or Cancer Outcomes Research, Fred Hutchinson Cancer Research
Background to the Task Force
In 2005, ISPOR published the Good Research Practices for Cost-
Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-
CEA Task Force report (http://www.ispor.org/workpaper/re
search_practices/Good_Research_Practices-Cost_Effectiveness_
Analysis_with_Clinical_Trials.pdf) to address issues related to
trial design, selecting data elements, database design and
management, analysis, and reporting of results. The findings
included the following: trials should be designed to evaluate
effectiveness (rather than efficacy), should include clinical
outcome measures, and should obtain health resource use
and health state utilities directly from study subjects. Collection
of economic data should be fully integrated into the study.
Analyses should be guided by an analysis plan and hypotheses.
An incremental analysis should be conducted with an
intention-to-treat approach. Uncertainty should be character-
ized. Articles should adhere to established standards for
reporting results of cost-effectiveness analyses.
After 9 years, the cochairs determined an update was
appropriate. They submitted a proposal to the Health Science
Policy Council in January 2014 to review the methodological and
applied studies published since the original report. The
proposed new report would reflect the advances that should
be considered standard of care for these types of studies. The
ISPOR Board of Directors approved the proposal in Febru-
ary 2014.
The task force is composed of experts in designing and
conducting clinical trials, modeling, economic evaluation,
statistical methods, and quality-of-life research. Task force
members were selected to represent a diverse range of
perspectives, including public and private research centers,
academia, hospitals, and the pharmaceutical industry. Task
force members are also internationally based, and include
individuals from the United Kingdom, Sweden, Argentina,
Canada, and the United States.
The task force met approximately every 6 weeks by tele-
conference to develop an outline and discuss issues to be
included in the report. In addition, task force members met in
person at ISPOR International meetings and European con-
gresses. All task force members reviewed many drafts of the
report and provided frequent feedback in both oral and written
comments.
Preliminary findings and recommendations were discussed
in a forum presentation at the 2014 ISPOR Annual European
Congress in Amsterdam. In addition, written feedback was
received from the first and final draft reports’ circulation to the
ISPOR Economic Evaluation Review Group. The task force
discussed comments on a series of teleconferences and in
person at the ISPOR Amsterdam Conference. All comments
were considered, and most were substantive and constructive.
Comments were addressed as appropriate in subsequent
versions of the report. All written comments are published at
the ISPOR Web site on the task force’s Webpage: http://www.
ispor.org/TaskForces/Cost_Effectiveness_Analysis_Clinical_Trials-
GRPIITF.asp. The task force report and Webpage may also be
accessed from the ISPOR homepage (www.ispor.org) via the
purple Research Tools menu, ISPOR Good Practices for Out-
comes Research, heading: Economic Evaluation Methods.
Table 1 – Signiﬁcant updates to 2014 Task Force
Report since the 2005 ISPOR RCT-CEA Task
Force Report.
Trial design
 Developments in improving external validity of trial-based CEA
 Considerations regarding value-of-information (VOI) analysis for
sample size calculations
 Discussion of appropriate comparator characteristics
 Additional considerations for timing of health economic data
collection
Data elements and database management
 Use of VOI analysis to help determine value of sample
information
 Use of electronic medical records and other new technologies for
data collection
 Discussion of mapping disease-speciﬁc instruments to
preference weights
 Collection of provider-, site-, and jurisdiction-speciﬁc data
Analysis
 Recent approaches to analyzing preference scores
 Examples for modeling outcomes beyond the time horizon of
the trial
 Use of provider-, site-, and jurisdiction-speciﬁc data in cross-
country transferability adjustments
 Additional approaches to select subgroup analysis
 Expanded uncertainty analysis section
Reporting
 Addition of Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) elements
References
 Added 70 new references across most topics
CEA, cost-effectiveness analysis; RCT, randomized controlled trial.
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party payments, patients will have very limited access to new
treatments. In addition, the number of audiences for clinical and
economic trials is growing, and now include governments, third-
party insurers, delivery systems, health care professionals, and
patients. Thus, there is an increased focus on whether economic
results from clinical trials are externally valid for different juris-
dictions. Furthermore, the growing prevalence and cost of chronic
progressive diseases such as rheumatoid arthritis, multiple
sclerosis, and cancer has increased the number of economic
evaluations that are based on a combination of clinical trial data
and external data representative of routine clinical practice [2].
Finally, the increasing number of randomized trials that evaluate
comparative effectiveness in clinical practice, for example, using
data from patient registries, provides new opportunities for
economic evaluations alongside randomized controlled trials
(RCTs) [3,4].
To foster improvements in the conduct and reporting of trial-
based economic analyses, the International Society for Pharma-
coeconomics and Outcomes Research (ISPOR) published the Good
Research Practices for Cost-Effectiveness Analysis Alongside
Clinical Trials: The ISPOR RCT-CEA Task Force report in 2005 [5].
To address changes in standards for designing, conducting, and
reporting cost-effectiveness in clinical trials, ISPOR initiated an
update of the report in 2014 to include the methodological
developments over the last 9 years. This report’s recommenda-
tions reﬂect advances in several areas related to trial design,
selecting data elements, database design and management,
analysis, and reporting of results (see Table 1).
The intended audience for this report is researchers in
academia, industry, and government who design and implement
these studies, decision makers who evaluate clinical and eco-
nomic evidence for reimbursement and formulary coverage
policies, and students.
The authors recognize that advances in methodology for joint
clinical/economic analyses will continue and that clinical/
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report highlights areas of consensus, emerging methodologies
with a diversity of professional opinions, and issues for which
further research and development are needed.
Common issues that are fundamental to all CEAs, such as
choice of discount rate for costs and outcomes or types of costs
that will be included (direct medical and nonmedical, indirect
costs for loss of productivity, etc.), will not be addressed in this
article. These topics are well described elsewhere [6].Initial Trial Design Issues
The quality of economic information that is derived from trials
depends on attributes of the trial’s design. The commonly used
phrase that economic analyses are conducted “alongside” clinical
trials is indicative of an important practical design issue: assessing
relative value is rarely the primary purpose of an experimental study.
Nevertheless, when the decision is made to conduct an economic
evaluation alongside a clinical trial, it is important that the
economic investigator contributes to the design of the study to
ensure that the trial will provide the data necessary for a high-
quality economic evaluation.
Appropriate Trial Design
The development of HTA as a method to inform decisions about
the use of medicines has put new demands on clinical trials.
Such studies focus on relative effectiveness; that is, studies
should directly compare effective interventions and should
include patients who are typical of day-to-day health care
settings. In some regions, speciﬁc guidelines that have implica-
tions for trial design have been developed for the early assess-
ment of pharmaceuticals [7].
It is generally acknowledged that pragmatic effectiveness
trials are the best vehicle for economic studies [8,9]. It is usually
necessary, however, to undertake economic evaluations earlier in
the development cycle when the focus is on efﬁcacy (including
phase III or even phase II drug trials), to provide timely informa-
tion for pricing and reimbursement.
Joint RCT-CEA evaluations can provide important information
for adoption decisions, including early evaluations (e.g., phases II
and III drug trials) when there are little or no additional data to be
synthesized, evaluations of trials with large enrollments and long
follow-up, and in cases in which trials reveal dramatic health
improvements for interventions such that very early posttrial
adoption is considered. Even trials that do not satisfy these
conditions may be valuable, particularly if they report their data
in such a way that their results can be synthesized with those of
other studies.
Some have questioned the use of clinical trials as a vehicle for
economic evaluations because of the often artiﬁcial nature of
trials and patient selection issues related to clinical practice
among other concerns [9]. Although these issues are important
challenges for trial-based economic evaluations, new develop-
ments have increased the value of such studies. During the last
decade, some HTA authorities and payers have had greater roles
and inﬂuence on the planning and design of early conﬁrmative
clinical trials [10,11]. The European Commission has funded the
Shaping European Early Dialogues for health technologies, for
early dialogues between member HTA agencies and developers of
pharmaceutical devices, and several pilot projects have been
conducted [12]. Although in formative stages, there is a growing
harmonization between the evidence requirements by regulators
and HTA/reimbursement agencies and payers, suggesting that in
the future, economic evaluations alongside RCT will also meet
objectives of external validity [13,14].When an economic investigator is asked to participate in
designing an economic evaluation alongside a clinical trial, he or
she should ﬁrst consider the extent to which that trial is likely to
be judged as an appropriate vehicle for an economic evaluation,
after adaptation in relevant aspects. Not all trials are appropriate
for economic analyses, for example, those that are exploratory in
nature such as dose ﬁnding studies, or have design issues that
limit their potential to affect clinical practice (and therefore of
limited interest to decision makers). For example, if so much
trial-speciﬁc health care is mandated that all potential differ-
ences in cost are overwhelmed, or if participants are followed
differentially on the basis of outcome, it is unlikely that an
economic assessment will be informative.
Identifying and Addressing Threats to External Validity/
Generalizability
The “artiﬁciality” of most clinical trials can pose serious threats
to external validity. These threats stem from1. protocol-driven resource use (which could bias costs in each
treatment arm upwards if included and downwards if
excluded, but it is generally difﬁcult to know how this will
bias the difference between treatments);2. comparators that are uncommon or not recommended in
clinical practice;3. recruiting that is not representative of the larger patient
population (e.g., large, urban, academic hospitals); inclusion
of study sites from countries with varying access and avail-
ability of health care services (e.g., rehabilitation, home care,
or emergency services);4. restrictive inclusion and exclusion criteria (patient population,
disease severity, comorbidities); and5. artiﬁcially enhanced compliance.
Perhaps most important among these factors is having a
relevant comparator, that is, one that represents best current or
most common practice (ideally both). The external validity can
best be increased by designing the trial to be more naturalistic,
that is, designed to evaluate the effectiveness of interventions in
real-life routine practice conditions [6,15].
Additional challenges arise with international trials. There
can be tremendous differences in treatment pathways, patient
and health care provider behavior, supply and ﬁnancing of health
care, and unit costs (prices) between countries [16–23]. Pooled
results may not be representative of any one country, but the
sample size is usually not large enough to analyze countries
separately. Such problems with heterogeneity are related to not
only economic evaluations but regulatory decisions as well [24].
The largest outcomes trials, however, are often international and
can provide excellent opportunities for meaningful economic
evaluation; many examples are available (e.g., [25–29]). Mitigation
of the threats mentioned is typically handled by a careful
combination of identifying country-speciﬁc resource types, cost
drivers, and unit costs—often via consultation with country-
speciﬁc clinical and economic experts during the design phase
—and proper analytical approaches, as discussed subsequently.
Sample Size and Power
In an ideal world, the economic appraisal would be factored into
sample size calculations using standard methods [30,31] based on
asymptotic normality, value of information [32,33], or simulation
[34]. It is common for the sample size of the trial, however, to be
based on primary clinical outcomes alone. As a consequence, the
economic comparisons can be underpowered. In cases in which
researchers wish to set up formal hypotheses for economic
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(e.g., $50,000 or $100,000/quality-adjusted life-year [QALY]) and
the power to detect when incremental analysis meets or exceeds
those thresholds [35]. Depending on the intended audience for
the evaluation, power calculations may also be useful for cost-
related end points.
Recently, economic investigators have become interested in
Bayesian techniques for specifying the appropriate sample size for
economic evaluation based on value-of-information methods [36–
38]. These methods have become popular in the methodological
literature, but have not yet been used routinely in practice. Although
value of information is compelling at a theoretical level, and is
worthy of mention in relation to some other areas covered below,
there can be many practical challenges associated with its use [39].
Study End Points and Comparators
The choice of the primary end point in a clinical study is unlikely to
correspond with the ideal end point for economic evaluation. For
example, the use of composite clinical end points is common in
clinical trials (e.g., fatal events and nonfatal events combined) to
provide greater statistical power. Cost per composite clinical end
point, however, is often an unsatisfactory summary measure for an
economic analysis, in part because the different outcomes are rarely
of equal importance. In addition, economic evaluation of surrogate
end points that are not well linked to ﬁnal end points is not
recommended (e.g., progression-free survival for many cancers). It
is recommended that clinical end points used in economic evalua-
tions be presented in disaggregated form, and that end points are
included that can be used to determine value in a commonmeasure
that allows comparison across treatments and diseases.
Clinical end points that focus on the impact of a treatment on
how a patient feels, functions, and survives are most useful for
an economic evaluation [40]. We recommend weighting end
points (e.g., by utilities) so that they yield a measure of QALYs
in the case of CEA, or a monetary beneﬁt measure in the case of
cost-beneﬁt analysis. For example, preference-weighted quality-
of-life scores are typically collected within the trial at regular
intervals, for example, every 3 months if there is an expectation
of rapid change and less frequently when changes are expected
to have reached a steady state. The resulting scores can be
combined with data on survival to estimate QALYs.
If possible, intermediate or surrogate end points (e.g., percent
cholesterol reduction) as the measure of beneﬁt should be
avoided. Intermediate outcome measures, however, are often
used when the costs of conducting a long-term trial are prohib-
itive. When use of intermediate outcomes or surrogate end points
is unavoidable, additional evidence is needed to link them with
long-term costs and outcomes. If such a link is not reliable or is
unavailable, the economic investigator should argue for follow-
up sufﬁcient to include clinically meaningful disease end points.
There is little that differentiates the choice of a comparator for
trials versus other types of CEAs. As already noted, the ideal
comparator likely is one that is widely used in practice. But even
this relatively uncontroversial recommendation can be problem-
atic for those trials for which there is disagreement about the
acceptability or cost-effectiveness of potential comparators. In
general, if there is ﬂexibility within the trial as to the choice of a
comparator, selecting one that most represents practice in the
region(s) of interest is recommended.
Appropriate Follow-Up
Economic analyses ideally include lifetime costs and outcomes of
treatment. Yet, clinical trials rarely extend beyond a few years and
are often conducted over much shorter periods. In practice, con-
sideration of the follow-up period for the trial involves therelationship between intermediate end points gathered in the
short run and long-term disease outcomes—the stronger that
relationship, the more a reliance on intermediate end points can
be justiﬁed.
A key design consideration is to determine the appropriate
points at which to gather medical resource use and data to
measure health-related preference weights. Practical considera-
tions include the use of scheduled contacts to collect information
direct from patients, ensuring that data collection points coincide
with expected changes in health-related quality of life (HRQOL)
(where QALYs are to be estimated from attaching weights to
clinical events) and that frequency is sufﬁcient to minimize
problems associated with patient recall [41,42]. It is recommended
that baseline measures of HRQOL and medical resource use (e.g.,
at the point of enrollment in the trial) be collected. Any QALY
analysis should adjust for any baseline imbalance in HRQOL [43],
and baseline measures of medical resource use can be used to
reduce the variance in incremental cost estimates [44]. Measure-
ment of resources and preferences must be frequent enough to
capture important changes in consumption and HRQOL, such that
reasonable estimates of area under the curve can be constructed.Data Elements
Prospective collection of patient-level resource use and health
preference–based data within a clinical trial requires careful
planning. Decisions about which data elements to collect should
be driven by their potential to affect the results of the study. One
approach for identifying these elements is to conduct or review
analyses of resource use patterns in routine practice to identify
cost drivers and cost variation between patients. When resources
and time allow, a decision model can be used to estimate the
expected value of this (sample) information. Within the model,
the economic investigator can apply a range of values for one or
more model parameters expected to be generated from the trial,
along with incremental costs for data collection, to compare the
expected net beneﬁt with new (sampled) information from the
trial versus the expected net beneﬁt with existing information
[45,46]. In practice, however, economic investigators may not
have been consulted early enough to allow adequate time or
resources to carry out a value-of-information analysis.
Patient-Level Data: Resource Use
Consistent with our previous report, we recommend prioritization
of high-cost resources as well as those that are expected to differ
between treatment arms, without distinction as to whether they
are related to disease or intervention [44]. The scope of resources
considered should include direct medical and nonmedical resour-
ces and indirect or productivity costs across patients and care-
givers. Nonmedical resources and productivity effects can be
particularly important if the intervention requires substantial
commitments on the part of patients and caregivers (e.g., long
travel times and intensive home therapy) relative to direct
medical care. Their relevance will be driven by the study per-
spective(s) planned for the economic evaluation, as related to the
study question. Although we acknowledge pragmatic pressures to
streamline data collection in clinical trials, we caution against
narrow collection of resources given that the treatment may have
unanticipated effects and the trial may offer the last opportunity
to collect these data within a randomized study design.
The frequency with which resource use data are collected
should account for the levels of resource usage expected among
patients enrolled in the trial, the ability to verify patient-reported
data through electronic medical records or other sources, and the
characteristics (e.g., cognitive abilities) of the trial participants. To
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should consider using memory aids such as diaries to record
medical visits and events, and should inform participants that
they will be asked to report this information throughout the trial
[47]. Based on our experience, it is often most feasible to schedule
reporting for various types of resources over the same period of
follow-up and coincide with trial visits. In any case, the time
horizon over which resource use and cost are collected should be
carefully deﬁned and include the entire time period between
collection points.
Resource use data are typically collected using a trial’s case
report form. The level of overlap between data elements crucial
to both clinical and economic outcome assessments typically
obviates consideration of separate data collection protocols.
Given that most case report forms are customized for each trial,
data collection processes are typically not validated and can lead
to variability in the content and quality of the information [48].
This variability reduces the ability to pool resource use data
across studies and to make direct comparisons between studies.
To improve the quality and uniformity of data generated from
trials, we recommend using validated instruments for resource
data collection [49–51] or when incorporating productivity costs
[52–54]; for resource data collection, use secondary sources when
possible to conﬁrm the utilization reported by patients.
Patient-Level Data: Preference-Based Outcomes
Information to derive individual-level preference weights should
be collected from patients participating in the trial to generate
QALYs for a cost-utility analysis. Preference-weighted health
state classiﬁcation systems are more widely used in clinical trials
than are direct elicitation methods such as time trade-off or
standard gamble because they are both easier to administer and
are considered to yield a measure of preferences from the general
public. Examples of these classiﬁcation systems include the
EuroQol ﬁve-dimensional questionnaire [55], including its newly
developed ﬁve-level version, which may be more sensitive to
changes in health status than is the three-level version [56,57],
any of the three versions of the health utilities index [58–60], the
Quality of Well-Being Scale [61,62], the six-dimensional health
state short form (derived from short-form 36 health survey)
[63,64], or the recently introduced Assessment of Quality of
Life-8D [65]. As with resource use data, the frequency with which
these measures are administered will depend on the medical
condition under study and the expected timing of effects from
the treatments being evaluated.
The literature on mapping disease-speciﬁc instruments to
preference weights has grown extensively over the last several
years, largely to address concerns that generic instruments do not
represent relevant dimensions of health for speciﬁc conditions
and are thus not responsive to changes that can be detected with
disease-speciﬁc instruments [66,67]. Although we acknowledge
the need for valid and reliable preference instruments that reﬂect
important changes in health status across conditions, a wide
range of methodological approaches to and concerns about this
mapping remain. Many regression-based mapping algorithms
exhibit poor model ﬁt [68], generate biased estimates [69], and
underestimate actual variance [70]. Few have undergone external
validation [71,72]. Given these concerns, economic investigators
may wish to consider coupling a disease-speciﬁc instrument with
a generic instrument to allow for scenario analysis.
In cases in which preference weights based on generic or
disease-speciﬁc instruments may not seem appropriate (e.g.,
interventions in which the process of care may affect utility),
economic investigators must also consider whether to apply
preference weights derived from traditional time trade-off and
standard gamble exercises or newer valuation methods such asdiscrete choice experiments [73,74]. For multinational trial analy-
ses or adaptations, economic investigators should consider
whether country-speciﬁc estimates may be desirable for the
stakeholders who will review the results from the analysis [28,75].
Patient-Level Data: Data Collection/Tracking
Technological advances offer the possibility of tracking resource
use, time estimates, and health status directly from trial partic-
ipants via the Web, smartphones, or mobile health applications.
These options offer the possibility of collecting relevant data
more proximate to the time when clinical events occur, at more
frequent intervals, or at random times throughout the day,
potentially increasing accuracy and reducing recall bias [76].
Research is needed to validate and compare these technology-
enabled data collection methods to traditional self-report and
interview strategies [77,78].
Provider-, Site-, and Jurisdiction-Level Data
As the trend continues toward more multisite and more global
representation in clinical trials, concerns about generalizability
and transferability have grown [28,75,79]. To provide greater
contextual information about participating providers and sites
and to enable investigation into factors that may affect the net
economic beneﬁt of a given intervention across jurisdictions, we
encourage economic investigators to collect additional provider-
level, site-level, or country-level information on practice patterns
and resource use.
Valuation of Resources
Trial-based economic evaluations require the ascertainment of
unit costs (or price weights) to value resources. The speciﬁcity of
unit costs will be dependent on the level of resource use data
collected within the trial, the perspective of the study, the avail-
ability of the estimates, the time horizon, and the acquisition costs
required to obtain the estimates [15,80]. For inpatient care, medical
tests and procedures, bundled payments systems, or classiﬁcations
such as Diagnosis Related Groups, Healthcare Resource Groupings,
or International Statistical Classiﬁcation of Diseases and Related Health
Problems codes are often used to map resource use to appropriate
unit costs. Although costs may be highly correlated between some
coding systems [81], the level of speciﬁcity of coding systems varies
for speciﬁc medical events, and economic investigators must be
careful to consider the impact that different systems can have on a
study’s ﬁndings [82,83].
The approach to valuation/assignment of unit costs to med-
ical and nonmedical resources requires trade-offs across accu-
racy, feasibility, generalizability, and cost [15,84]. In many cases,
adjustment for differential timing, imputation for estimates that
are not available, adaptation to different settings or coding
systems (e.g., Diagnosis Related Groups to Healthcare Resource
Grouping and International Classiﬁcation of Diseases, Ninth Revision
to International Statistical Classiﬁcation of Diseases, 10th Revision),
and conversion to different currencies may be necessary before
assigning unit costs to quantities of resource. In other cases,
particularly for new medical interventions, supplemental micro-
costing exercises may be necessary to develop accurate cost
estimates. Drummond et al. [15], Glick et al. [44], and Luce et al.
[84] provide useful references on issues related to costing.Database Design and Management
The full integration of clinical and economic data helps to ensure
high-quality processes to obtain valid and complete data across study
sites. Data capture for clinical trials is increasingly electronic and
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enter data into an electronic case report form that is transmitted to a
central trial database. These systems provide the opportunity for
database programmers to apply real-time edit checks and queries to
minimize errant data from sites and to alert sites to data elements
that may be missing or overdue. We strongly recommend early and
regular monitoring of economic data collection.
The next generation of electronic data capture includes the
use of electronic health record data to (partially) populate clinical
trial databases and the development of distributed data networks
that do not require the data to be transferred to a central data
repository for analysis [85,86]. Although these new models could
drastically improve the efﬁciency of large-scale clinical trials,
future studies will be needed to understand the meaning, quality,
and completeness of data to support trial-based economic
evaluations.
Informed consent for clinical trials should be inclusive of
language to allow for collection of medical resource use and
HRQOL data. In cases in which trial data can be augmented with
hospital bills, health claims, or productivity reports for the
economic evaluation, explicit language must be included in
patient consent forms to allow the release of these data.
Whether data are collected by paper or electronically, consis-
tency across data elements collected for clinical, economic, and
safety end points is crucial. As such, early and ongoing collabo-
ration among economic investigators carrying out disparate
analyses is necessary to ensure that reliable results are generated
across studies.
If trial investigators plan to release patient-level trial records
at some point following the publication of trial results, consid-
eration should be made as to whether economic data can also be
released without compromising patient conﬁdentiality. Such
release of patient-level records would aid with subsequent
modeling and meta-analyses.Analysis
Guiding Principles
The analysis of economic measures should be guided by a data
analysis plan. A prespeciﬁed plan is particularly important if
formal tests of hypotheses are to be performed. Any tests of
hypotheses that are not speciﬁed within the plan should be
reported as exploratory. The plan should specify whether gener-
alized linear model, least squares regression, or other multi-
variable analysis will be used to improve precision and to adjust
for treatment group imbalances. The plan should also identify
any selected subgroups and state the type of analysis, for
example, intention-to-treat or modiﬁed intention-to-treat, that
will be conducted. The plan should be ﬁnalized before trial data
are unblinded; publication of the analysis plan before the com-
pletion of the trial is a best practice [87–89].
Although it is unlikely that all studies will use the same
approaches for the analysis of resource use, cost, preference, and
cost-effectiveness, there are several analysis features that should be
common to all analyses of economic data derived from clinical trials:1. The intention-to-treat population should be used for the
primary analysis.2. A common time horizon(s) should be used for accumulating
costs and outcomes; a within-trial assessment of costs and
outcomes should be conducted, even when also modeling or
projecting beyond the time horizon of the trial.3. An assessment of uncertainty is necessary for each measure
(standard errors or conﬁdence intervals for point estimates; P
values for hypothesis tests).4. A (common) real discount rate should be applied to future
costs and, when used in a CEA, to future outcomes.5. If data for some subjects are missing and/or censored, the
analytic approach should address this issue consistently in
the various analyses affected by missing data.
Trial Costs
The purpose of clinical trial cost analysis is to estimate costs, cost
differences associated with treatment, the variability of differ-
ences, and test whether the differences occurred by chance.
Once resources have been identiﬁed and valued, differences
between groups must be summarized. Sample/arithmetic mean
cost differences are generally considered the most appropriate
and robust measure [90]. Nevertheless, cost data often do not
conform to the assumptions for parametric statistical tests for
comparing differences in arithmetic means [44,91–93]. They are
usually right-skewed because it is impossible to incur costs less
than zero and there are typically small numbers of high-
resource-use patients. In addition, if subsets of data such as
hospitalizations are being analyzed, there can be excessive
numbers of participants with costs equaling zero. In most cases,
the nonparametric bootstrap is an appropriate method to com-
pare means and calculate conﬁdence intervals [94–96] although
parametric methods provide a unique solution and have been
shown to provide coverage equal or superior to that provided by
bootstrap methods [97,98].
Other common nonparametric tests (e.g. Kruskal-Wallis or
Wilcoxon) compare medians (or other characteristics of the
distribution of cost), but not means and thus are less appropriate
[99–101]. Analyses of data that have been transformed to normal-
ize the distribution can translate between-group differences in
variance, kurtosis, and so forth into what appear to be differences
in means. Retransformation to the original scale of costs must
account for differences in variance and so forth and must include
transformation of error terms [102–106].
The same distributional issues that affect univariate analysis
of costs also affect use of costs as a dependent variable in
multivariable analysis. The underlying distribution of costs
should be carefully assessed to determine the most appropriate
approach to draw inferences about or estimate between-group
cost differences [107]. Generalized linear models commonly, but
not necessarily, using a log link and gamma family should be
considered for multivariable analysis of cost [103,108]. When
most subjects in the study have nonzero costs, ordinary least
squares can be used with other methods to provide a reference
point or a check of robustness of results. If differences in resource
use or subsets of costs are to be estimated, similar considerations
regarding the appropriateness of statistical approaches based on
distributional assumptions should be applied.
When study participants use large amounts of medical serv-
ices that are unrelated to the disease or treatment under study, it
may be difﬁcult to detect the inﬂuence of the treatment on total
health care costs. One approach to addressing this problem is to
conduct secondary analyses that evaluate costs that are consid-
ered related to the disease or treatment under study. If such
analyses are performed, it is important to prespecify services that
were deemed “disease-related,” and to display costs for each
component in the treatment and control arms.
Trial Outcomes
When one of the trial’s clinical end points is also used as the
outcome for the CEA (e.g., in-trial mortality), it is generally most
transparent to adopt the methods used in the clinical analysis for
the primary analysis plan, particularly if the clinical result is cited in
product labeling or a publication. In some cases, the clinical analysis
methods are not appropriate for economic analysis (e.g., the clinical
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economic analysis relies on absolute treatment differences, or the
clinical analysis focuses on time to ﬁrst event, whereas the eco-
nomic analysis considers all events). Composite measures of out-
come are also generally not appropriate for economic analyses. If
other outcomes are used for the economic analysis, the linkage
between clinical and economic measures should be clearly speciﬁed.
Using nonclinical effectiveness end points such as QALYs
involves both construction and analysis. Health state utilities/
preference scores, either collected directly from trial patients or
imputed on the basis of observed health states, can be trans-
formed into QALYs using standard area-under-the-curve meth-
ods [15,109]. As with the analysis of cost, multivariable analysis
should be considered for drawing inferences about or estimating
between-group differences in outcome. Generalized linear mod-
els, regression estimators based on features of the beta distribu-
tion [110], or limited dependent variable mixture models [111]
should be considered for the analysis of preference scores. As
stated previously, for the analysis of both costs and effects,
explanatory variables should include baseline measures of costs
or effects [43,44]. Analytic reﬁnements may include adjusting for
ceiling effects [112] and modeling of longitudinal effects [113,114].
Because failure to reject the hypothesis about the equality of
two therapies is not the same as ﬁnding that outcomes of two
therapies are identical, CEA should still be performed if the
clinical study fails to demonstrate a statistically signiﬁcant
difference in clinical end points [115,116]. In such situations, a
cost-minimization analysis can provide useful information to
those who are interested in understanding the budget impact
implications of the trial, but cost-minimization should not be the
primary or sole form of analysis.
Missing and Censored Data
Missing data are inevitable in economic analyses conducted
alongside trials. Such data can include item-level missingness
and missing because of censoring. In analyzing data sets with
missing data, one must determine the nature of the missing data
and then deﬁne an approach for dealing with the missing data.
Missing data may bear no relation to observed or unobserved
factors in the population (missing completely at random), may
have a relationship with observed variables (missing at random),
or may be related to unobserved factors (not missing at random)
[44,117]. Eliminating cases with missing data is not recom-
mended because it may introduce bias or severely reduce the
power to test hypotheses. Nevertheless, ignoring small amounts
of missing data (e.g.,o5% of the observations) is acceptable if the
amount and pattern of missing data are similar across treatment
groups and a reasonable case can be made that doing so is
unlikely to bias treatment group comparisons.
Imputation refers to replacing missing ﬁelds with estimates. If
one chooses to impute missing data, most experts recommend
multiple imputation approaches because they reﬂect the uncer-
tainty that is inherent when replacing missing data [118–120].
Most commonly used statistical software packages include pro-
grams for imputation of missing data. A review of these programs
can be found at http://www.multiple-imputation.com [121].
Censoring can be addressed with a number of approaches
[122,123]. Most assume that censoring is either completely at
random [124] or at random [123,125–128]. Nevertheless, nonran-
dom censoring is common, and external data sources for similar
patients may be required to both identify and address it.
Summary Measures
One or more summary measures should be used to characterize
the relative value of treatments in the clinical trial. Three generalclasses of summary measures are available that differ in how
incremental costs and outcomes are combined into a single
metric:1. Ratio measures (e.g., incremental cost-effectiveness ratios) are
obtained by dividing the incremental cost by the incremental
health beneﬁt.2. Difference measures (e.g., net monetary beneﬁts) rely on the
ability to deﬁne a common metric (such as monetary units) by
which both costs and outcomes can be measured [129–131].3. Probability measures (e.g., acceptability curves) characterize
the likelihood the new treatment will be deemed cost-
effective based on incremental costs and outcomes [132,133].
The difference measures and probability measures are calcu-
lated for speciﬁc values of “willingness-to-pay” or cost-
effectiveness thresholds. Because these values may not be known
and/or vary among health care decision makers, one should
evaluate the summary measure over a reasonable range of values.
Uncertainty
Results of economic assessments in trials are subject to a number
of sources of uncertainty, including sampling uncertainty, uncer-
tainty in parameters such as unit costs and the discount rate, and
—whenmissing data are present—imputation-related uncertainty.
Sampling Uncertainty
Because economic outcomes in trials are the result of a single
sample drawn from the population, one should report the
variability in these outcomes that arises from such sampling.
Variability should be reported for within-group estimates of costs
and outcomes, between-group differences in costs and outcomes,
and the comparison of costs and outcomes. One approach for
reporting this variability is to construct a conﬁdence interval for
the cost-effectiveness ratio or for net monetary beneﬁt or to
construct an acceptability curve. A second is to quantify the value
of eliminating the uncertainty by estimation of the expected
value of information.
Conﬁdence intervals for cost-effectiveness ratios, conﬁdence
intervals for net monetary beneﬁt, and acceptability curves are
different, but related, measures that allow us to identify whether
we can be conﬁdent that a therapy’s cost per unit of outcome, for
example, a QALY, is less than one’s maximum willingness to pay.
Both parametric and nonparametric methods can be used to
construct these measures [44,134–136]. Decision makers can thus
identify values of willingness to pay for which they 1) can be
conﬁdent that the therapy is good value for the cost; 2) can
be conﬁdent that the therapy is not good value; and 3) cannot be
conﬁdent that the therapies’ values differ from one another. One
advantage of the conﬁdence interval for the cost-effectiveness ratio
is that its limits deﬁne these values of willingness to pay; one
advantage of the acceptability curve is that it deﬁnes these values
for varying levels of conﬁdence that range from 0% to 100%.
Value of information allows quantiﬁcation of the value of
eliminating the uncertainty that exists in the data [32,45,137].
Results of value-of-information analyses can help decision makers
determine how much they should be willing to spend for research
meant to increase our certainty, to prioritize research across
disease areas, and to identify speciﬁc sources of uncertainty that
are more and less important to target for further research [138,139].
Parameter Uncertainty
Uncertainty should be assessed for any parameter estimates that,
when varied, have the potential to inﬂuence policy. Examples
include unit costs and the discount rate. One approach to this
assessment is sensitivity analysis: for example, if one uses a
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assumption by repeating the analysis but using a 1% rate or a
5% rate.
A second approach is the assessment of the value of informa-
tion related to parameter uncertainty (expected value of partial
perfect information) [140]. Measures of sampling uncertainty and
sensitivity analysis for parameter uncertainty are complements,
not substitutes. Thus, when conducting sensitivity analysis, one
should report both the revised point estimate and revised 95%
conﬁdence intervals that result from the sensitivity analysis.
Imputation Uncertainty
Finally, some methods used to address missing or censored data
(e.g., use of an imputed mean) may artiﬁcially reduce estimates of
sampling uncertainty. One should make efforts to address this
shrinkage when reporting sampling uncertainty, for example, by
bootstrapping the entire imputation and estimation process.
Estimating Country-Speciﬁc Costs for Multinational Studies
It is common to apply country-speciﬁc unit costs for pooled trial
resource use to estimate country-speciﬁc costs. In practice, this
approach yields few qualitative differences in summary meas-
ures of cost-effectiveness among countries with similar levels of
economic development but may not adjust for important
country-speciﬁc differences [141,142]. Rather, intercountry differ-
ences in population characteristics and treatment patterns are
more likely to inﬂuence summary measures between countries
rather than differences in unit costs. Recommended approaches
to address this issue include [141,143–145]1. hypothesis tests of homogeneity of results across countries
(and adjusting the resource use in other countries to better
match those seen in country X);2. multivariable cost or outcome regressions to adjust for coun-
try effects (e.g., include country dummies or adjusted gross
national product per capita as covariates); and3. multilevel random effects model with shrinkage estimators.
All three methods allow for the inclusion of site-speciﬁc
characteristics that are recommended in the “Provider-, Site-,
and Jurisdiction-Level Data” section.
Including Costs and Effects beyond the Time Horizon of the
Trial
The cost-effectiveness observed within the trial may be substan-
tially different from what would have been observed with
continued follow-up. Well established, published models (pre-
ferred) or those developed speciﬁcally for the trial are used to
project costs and outcomes that could have been observed had
observation been prolonged. When modeling beyond the follow-
up period for the trial, it is important to project costs and
outcomes over the expected duration of treatment and its effects.
Direct modeling of long-term costs and outcomes is feasible
when the trial period is long enough, or if at least a subset of
patients are observed for a longer time and provide a basis for
estimating other patients’ outcomes. A number of approaches are
feasible [146]. Parametric survival models estimated on trial data
are generally recommended for such projections, unless models
based on other data or methods can be justiﬁed [147,148].
In cases in which such direct modeling is not feasible, it may
be possible to “marry” trial data to long-term observational data
in a model. In either case, good modeling practices should be
followed. Examples of projection models used for trials include
those from clopidogrel versus aspirin in patients at risk of
ischaemic events [149], Global Utilization of Streptokinase andTissue Plasminogen Activator for Occluded Coronary Arteries
[150], EPlerenone’s neuroHormonal Efﬁcacy and SUrvival Study
[27], Sudden Cardiac Death in Heart Failure Trial [151], and the
National Emphysema Treatment Trial [152]. The reader is
referred to the consensus position of the ISPOR Modeling Good
Research Practices Task Force reports for discussion of modeling
issues [153–159].
Cost-effectiveness ratios should be calculated at various time
horizons (e.g., 2, 5, 10 years, or as appropriate for the episode of
the disease), both to accommodate the needs of decision makers
and to provide a “trajectory” of summary measures over time.
The effects of long-term health care costs (i.e., after the episode
of care) not directly related to treatment should be taken into
account as well as possible [160]. As always, assumptions used
must be described and justiﬁed, and the uncertainty associated
with projections must be taken into account.
Subgroup Analysis
Proper subgroup analysis can be vital to decision makers [161]
and should be prespeciﬁed. Nonetheless, the dangers of spurious
subgroup effects are well known. For example, the probability of
ﬁnding a statistically signiﬁcant difference due solely to random
variation increases with the number of differences examined
unless the alpha level is adjusted appropriately. The focus should
be on testing treatment interactions on the absolute scale, with a
justiﬁcation for choice of scale used. In cases in which prespeci-
ﬁed clinical interactions are signiﬁcant, subgroup analyses may
be justiﬁed. Methods [162] include stratiﬁcation by subgroup
[163], n-of-1 trials [164], latent mixture models [165], and Baye-
sian methods [166].Reporting the Methods and Results
Economic analysis has various audiences. Correspondingly, detailed
and comprehensive information on the methods and results should
be available to interested readers in a format that facilitates
interpretation. Journal word limits often necessitate parsimony in
reporting; therefore, we recommend that in addition to the main
report, detailed technical appendices be made available online.
A number of organizations including ISPOR have developed
minimum reporting standards for clinical trials and economic
analyses [167–171]. The principles and suggested format in these
guidance documents should be adhered to in the reporting of
economic studies. We have highlighted issues of particular impor-
tance to economic studies conducted alongside clinical trials.
Reporting of the methods and results should include elements
identiﬁed in the Consolidated Health Economic Evaluation
Reporting Standards statement [169,170].
Trial-Related Issues1. A brief, general description of the clinical trial, including
patients’ demographic characteristics, trial setting (e.g., coun-
try, tertiary care hospital), inclusion and exclusion criteria and
protocol-driven procedures that inﬂuence external validity,
intervention and control arms, time horizon for the interven-
tion and follow-up, and a link to the registry posting of the
trial (e.g., clinicaltrials.gov) and2. Key clinical ﬁndings.
Data for the Economic Study1. Delineation between data collected as part of the trial versus
data collected outside of the trial;
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collection;3. Source of unit costs, published utility weights; and
4. Amount of missing and censored data.
Methods of Analysis1. Construction of costs and outcomes, including the discount
rate used;2. In cases in which the main clinical end point is used in the
denominator of the incremental cost-effectiveness ratio and
different methods were used to analyze this end point in the
clinical and economic analyses, any differences in the point
estimates should be explained;3. Methods for addressing missing and censored data;
4. Statistical methods used to compare resource use, costs, and
outcomes;
5. Methods and assumptions used to project costs and outcomes
beyond the trial period; and
6. Deviations from the prespeciﬁed analysis plan and justiﬁca-
tion for these changes.
Results1. Resource use, costs, outcome measures, including point esti-
mates and measures of uncertainty;2. Results within the time horizon of the trial;
3. Results with projections beyond the trial (if conducted);
4. Graphical displays of results not easily reported in tabular
form (e.g., cost-effectiveness acceptability); and
5. Curves (joint density of incremental costs and outcomes).
For further guidance on reporting standards, please see Con-
solidated Health Economic Evaluation Reporting Standards
(CHEERS)—Explanation and elaboration: A report of the ISPOR
Health Economic Evaluations Publication Guidelines Good
Reporting Practices Task Force [169,171].
Finally, data from economic analyses performed in the con-
text of trials may also be used in independent cost-effectiveness
models based on decision analysis or meta-analyses [6]. To
facilitate synthesis of economic information from multiple trials,
authors should report means and standard errors for incremental
costs and outcomes and their correlation.Conclusions
Since publication of the ﬁrst ISPOR RCT-CEA Task Force report 10
years ago, the role and use of economics in health care coverage
and reimbursement decisions have increased substantially
around the world. The focus of this report was methods for
CEA conducted alongside randomized clinical trials designed to
test the efﬁcacy or effectiveness of drugs, devices, surgical
procedures, or screening interventions, including pragmatic tri-
als. This report provides guidance on the methods, with the goal
of making trial-based economic evaluation as useful as possible
for decision makers.
Most of the recommendations from the 2005 report remain
valid and appropriate. This report emphasizes innovations in
several areas, including the use of value-of-information techni-
ques, the increased role of diverse stakeholders in study design,
the use of newer multivariate methods, and standards for
modeling outcomes beyond the trial observation period.
This task force maintains that when designed, analyzed, and
interpreted appropriately, economic evaluations alongside
randomized clinical trials are important sources of informationfor decision makers. To be useful as a stand-alone evaluation,
however, a trial must be designed to represent the population,
duration of treatment, clinical practice, types of outcomes, and
other factors most relevant to the clinical situation to which the
decision is being applied. Similar caveats generally apply to the
clinical results of the trial. When these conditions are not
satisﬁed, modeling-based corrections can often adapt the results
to the conditions appropriate for the decision context.
Methods for designing, conducting, and reporting economic
analyses alongside RCTs will continue to evolve and improve
over time, reﬂecting changes in knowledge and the evolving
needs of decision makers. As these methods are identiﬁed,
tested, and validated, they will be included in future versions of
this guidance document [11].Acknowledgments
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